Eli Lilly (LLY) Selects ICON plc (ICLR) to Manage Clinical Trial Site Set Up and Monitoring in Europe
More News related to ICLR
- ICON Selected by Lilly to Oversee its Clinical Data Management in Japan
- ICON (ICLR) Posts Q3 EPS of $0.40; Guides FY09 EPS Above Street
- ICON Reports 14% Increase in EPS, and Raises Earnings Guidance for 2009
- Trading Radar for 10/21: Boeing (BA), eBay (EBAY), Wells Fargo (WFC), US Bancorp (USB), Eli Lilly (ELY), St. Jude Medical (STJ) Report
- Goldman Sachs Downgrades Parexel (PRXL) to Sell, Upgrades Charles River (CRL) to Neutral
More News related to LLY
- Widespread Generic Erosion of Atypical Antipsychotics Will Cause the Bipolar Disorder Drug Market to Decline By More Than $1 Billion Through 2018
- Oncology On Canvas(SM) Launches 2010 Art Competition for Individuals Touched by Cancer
- Trading Outlook for Avanir Pharmaceuticals Inc. Issued by InvestorSoup.com
- Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's BYETTA(R) (Exenatide) Injection Update
- Amylin (AMLN) Announces BYETTA Approved As Stand-Alone Medication
ICON plc, (NASDAQ: ICLR) today announced that it has signed a strategic partnership with Eli Lilly and Company (NYSE: LLY) to manage the company's clinical trial site set up and monitoring in Europe for Lilly managed studies. The agreement, which is subject to the relevant employee consultation processes, is a continuation of Lilly's ongoing transformation of its research and development organisation and follows Lilly's selection of ICON to manage its clinical data management business outside of the US, which was announced in November 2008.
Related Categories
Corporate NewsStocks Mentioned
-0.48
+0.07Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
